\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationAmsterdam (NL)
EFECS is the European Forum for Electronic Components and Systems. It is a yearly event focussed around R&D&I. This year it will be again a real-life event
You'll learn, discover and help to shape Our Digital Future online while we network! AENEAS, ARTEMIS and EPoSS joined forces, together with the associated organisers ECSEL JU, the European Commission and EUREKA, to create collaborative innovation through economic and societal challenges and to boost the European Digital Economy.
Discover the latest technology trends and applications of ECS, help shape the future of technology, network with the ECS community, learn what support is available and manage the ECS impact for a green transition of digitalisation.
EFECS 2022 will be an in-person rendez-vous of stakeholders from across the ECS community, including an inspiring programme with a focus on ECS for a green and competitive Europe, keynote speeches, high-level presentations, Pre-Brokerage activities and many more. And of course, this edition will also contain a networking marketplace for new project ideas and project dissemination.
More info and registration on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
